News
CYTK
71.41
+0.37%
0.26
Cytokinetics gains amid renewed takeover speculation
Seeking Alpha · 1d ago
Weekly Report: what happened at CYTK last week (0318-0322)?
Weekly Report · 3d ago
5 Stocks Hedge Funds Love and have Analysts Support
TipRanks · 6d ago
2 Incredible Growth Stocks to Buy Right Now
Cytokinetics and Viking Therapeutics are top biotech stocks to buy right now. The Federal Reserve is expected to pivot on interest rates in 2024. This event could act as a significant catalyst for biotech stocks. Viking's shares have surged 261% this year due to the weight loss drug market. The company's shares are undervalued.
The Motley Fool · 03/20 12:30
3 Potential Biotech Buyout Targets In 2024
Biotech sector saw a surge of M&A activity at the end of 2023. The small biotech sector surged by 50% off its late October lows. 2024 should be a solid year for acquisitions in the biotech/biopharma space. Big drug makers have large cash balances and face key patent expirations. Three potential buyout targets in 2024 are highlighted below.
Seeking Alpha · 03/19 14:16
Weekly Report: what happened at CYTK last week (0311-0315)?
Weekly Report · 03/18 09:12
Cytokinetics: CEO Talks Down Buyout Prospects
Seeking Alpha · 03/16 07:43
Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS)
Analysts have new ratings on Amedisys, Cytokinetics and Coherus Biosciences. Truist Financial analyst David Macdonald maintained a Hold rating on the Healthcare sector. The company’s shares closed at $93.25 today.
TipRanks · 03/14 11:30
Cytokinetics drifts lower as CEO touts standalone strategy
Cytokinetics CEO Robert Blum says the biotech company's stock could have upside without a takeover. The biotech company has been a takeover target in recent months. Novartis (NVS) was in advanced talks to acquire the company in January. The company's shares slipped 3% on Monday.
Seeking Alpha · 03/11 19:54
Cytokinetics is Now Oversold (CYTK)
NASDAQ · 03/11 15:56
Notable ETF Outflow Detected - XBI, VKTX, IOVA, CYTK
NASDAQ · 03/11 14:50
Weekly Report: what happened at CYTK last week (0304-0308)?
Weekly Report · 03/11 09:12
Cytokinetics Price Target Cut to $77.00/Share From $78.00 by JP Morgan
Dow Jones · 03/07 19:25
Cytokinetics Is Maintained at Overweight by JP Morgan
Dow Jones · 03/07 19:25
JP Morgan Maintains Overweight on Cytokinetics, Lowers Price Target to $77
Benzinga · 03/07 19:16
Cytokinetics Is Maintained at Buy by Mizuho
Dow Jones · 03/06 13:22
Cytokinetics Price Target Cut to $99.00/Share From $103.00 by Mizuho
Dow Jones · 03/06 13:22
Mizuho Maintains Buy on Cytokinetics, Lowers Price Target to $99
Benzinga · 03/06 13:12
Truist Financial Gives a Buy Rating to Cytokinetics (CYTK)
TipRanks · 03/05 12:25
Cytokinetics Price Target Maintained With a $107.00/Share by Oppenheimer
Dow Jones · 03/04 13:55
More
Webull provides a variety of real-time CYTK stock news. You can receive the latest news about Cytokinetics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CYTK
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.